Bolt Biotherapeutics(BOLT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers • Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting • Cash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, CA, Aug. 13, 2024 – Bolt ...